

HPAP-101- Donor Summary



HPAP	101	UNOS	
Recovery OPO	One Legacy	Allocation Via	UPENN <input type="checkbox"/> nPOD <input checked="" type="checkbox"/>
Age (years)	55	DCD	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
Race	Hispanic	DBD	YES <input checked="" type="checkbox"/> NO <input type="checkbox"/>
Sex	M <input type="checkbox"/> F <input checked="" type="checkbox"/>	Admission to Cross Clamp	207 Hours 36 Mins.
ABO (Rh)	B+	Cross Clamp Time	7/15/21 03:59 EST
BMI (Kg/m²) Weight (kg) Height (cm)	38.01 100.60 162.56	Cold Ischemia Time*	29 Hours 07 Mins.
Cause of Death	Cerebrovascular/Stroke	Preservation Solution	UW <input type="checkbox"/> HTK <input type="checkbox"/> NA
Mechanism of Injury	Intracranial Hemorrhage/Stroke	Organs Recovered	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input checked="" type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Cardiac Arrest/Downtime	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity:	<input type="text"/> Hours <input type="text"/> Mins. NA
CPR / Time	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	Organs Discarded	Heart <input type="checkbox"/> Kidney <input type="checkbox"/> Lung <input type="checkbox"/> Pancreas <input type="checkbox"/> Liver <input type="checkbox"/> Intestine <input type="checkbox"/>
Total Est. Downtime	No Downtime	Blood Culture	No Growth
Date /Time of Admission	07/06/2021 09:23 PST 07/06/2021 12:23 EST	PHS High Risk	YES <input type="checkbox"/> NO <input checked="" type="checkbox"/>
		Acute Lung Injury	Bibasilar chronic interstitial changes

*Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



HPAP-101- Donor Summary

Medical History:

		Duration	Medications	Compliance
Type of Diabetes	-----	-----	-----	-----
History of cancer	-----	-----	-----	-----
CAD	-----	-----	-----	-----
Hypertension	-----	-----	-----	-----
Hyperlipidemia	-----	-----	-----	-----
Autoimmune disease				
Family History	CAD <input type="checkbox"/>	Diabetes <input type="checkbox"/>	Auto immune disease <input type="checkbox"/>	Others:
Surgical History:	Aneurysm corrective surgery1990, Back surgery to repair and fuse discs in lumbar spine2015, Abdominal hysterectomy DVT/PE - post surgery ,Right knee replacement surgery2020, Lasik eye surgery			
Comments:	Medical HX: GERD, migraines, asthma for 10years, chronic back pain- Norco use. Obesity, kidney stones 5 years ago. Medication Hx: Albutrol, Vicodin			

Hemodynamic Profile

Average BP During Hospitalization (mmHg)	127/72	
Average Low BP During Hospitalization	NA	Duration:
Average BP in OR (mmHg)	NA	
Average Low BP in OR (mmHg)	NA	Duration:
Average HR in OR (bpm)	NA	
ABG-pH range	7.2 5 - 7.50	

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	-----	-----	-----
PRBCs	-----	-----	309.00
Platelets	-----	-----	-----
Norepinephrine (Levophed)	-----	106	429.00
Vasopressin	-----	247.2	618.00
Neo-Synephrine	-----	-----	-----
Epinephrine	-----	-----	-----
Phenylephrine	-----	-----	-----
Dopamine	-----	-----	-----



HPAP-101- Donor Summary

Blood Products/Meds Transfused Intraoperative

Product	Amount (ml)	Units	Total (ml)
Fresh Frozen Plasma	NA	NA	NA
PRBCs	NA	NA	NA
Platelets	NA	NA	NA
Norepinephrine (Levophed)	NA	NA	NA
Vasopressin	NA	NA	NA
Neo-Syneprine (phenylephrine)	NA	NA	NA
Epinephrine	NA	NA	NA
Dopamine	NA	NA	NA
Heparin	NA	NA	NA

Initial Autoantibody Screening (nPOD): ELISA

Not performed for HPAP-T2D program

GAD-65	IA-2
ND	ND

Confirmatory results: Radioimmuno Assay (RIA)

	GAD-65 (unit/ml)	IA-2 (unit/ml)	Insulin AAB (unit/ml)	ZnT8 (unit/ml)
Results	0	0	-0.001	-0.007
Cut-off values	20	5	0.010	0.020

*Sample obtained at time of organ recovery.

	C-peptide (ng/ml)	Proinsulin
Results	11.08	ND

*Sample obtained at time of organ recovery.

HLA (OPO)*

Class 1	A	2	29	Class II	DR	13	13
	B	13	51		DR51	N-Negative	
	C	06	16		DR52	52	52
	Bw4	Positive			DR53	N-Negative	
	Bw6	Negative			DQB1	6	6
					DQA1	01	01
					DPB1	02:01	04:01
Comment:							

HPAP-101- Donor Summary



Confirmatory HLA (UPENN)*

Not performed for HPAP-T2D program

Class 1	A			Class II	DRB1		
	B				DRB3		
	C				DRB4		
					DRB5		
					DQB1		
					DQA1		
					DPB1		
					DPA1		

*HLA typing performed using NGS

Infectious Disease Serology

Test	Result	Hemo/Plasma Dilution Status	
		Qualified	Non-Qualified
EBV IgG	Positive	✓	-
EBV IgM	Positive	✓	-
CMV	Positive	✓	-
HBcAb	Non Reactive	✓	-
HBsAg	Non Reactive	✓	-
HCV Ab	Non Reactive	✓	-
HIV I/II	Non Reactive	✓	-
Syphilis	Non Reactive	✓	-
Procleix Ultrio	ND	-	-
Ultrio HBV	Non Reactive	✓	-
Ultrio HCV	Non Reactive	✓	-
Ultrio HIV	Non Reactive	✓	-
Toxoplasma Ab	Negative	✓	-
SARS-CoV-2	Negative	✓	-



HPAP-101- Donor Summary

Laboratory Panel

	Initial	Peak	Terminal
Na (mEq/L) (135-145)	143	162	133
Creatinine (<1.5)	0.90	1.10	1.10
Glucose (mg/dL) (60-150)	107	248	248
HbA1C%	5.0	-----	-----
Total bilirubin (0-1.0)	0.8	2.1	1.1
SGOT (AST) (0-40)	52	63	48
SGPT (ALT) (5-35)	39	39	34
Alkaline phosphatase (45-110)	74	103	103
Serum Amylase (23-851)	102	202	142
Serum Lipase (0-80)	115	246	146
WBC (THO/uL) (4.5-11.0)	2.2	4.6	3.9
Hgb (g/dL) (12-16)	13.7	13.7	7.1
Platelets (THO/uL) (150-350)	151	151	133
INR (<2.0)	1.40	1.40	1.30

Urinalysis

	1 st	2 nd	3 rd	4 th
Glucose	Negative (X 2)	50 (x3)	>=500	Negative(x5)
	5 th	6 th		
	50	Negative(x2)		

Medications During Hospitalization

Steroids**	Solumedrol 500mg Q8		
Diuretics	Lasix 60 - 400 mg		
T3 Protocol	-----		
T4 Protocol*	-----		
Insulin**	5-16 unit/hr for the duration of 52 hrs		
Antihypertensive	Cardene 2.5-5 mg		
Vasodilators	-----		
DDAVP**	-----		
Total parenteral nutrition	-----		
Other	Vancomycin 750mg Q12, Zosyn 3.375g Q8, Keppra 500 mg, Pepcid 20 mg, Hetastach 500 mg,	Specify	

*T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015;7 17-27.

** Excluding T4 Protocol